CMT Research Pipeline

Therapies Under Development in Industry

Therapy Pipeline

Small Molecule
Clinical Trials
Company
Name
CMT Type
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Applied Therapeutics
AT 007 (aldose reductase inhibitor)
Biallelic SORD mutations
Current stage: Phase 3
NMD Pharma
NMD670
1 and 2
Current stage: Phase 2
InFlectis BioScience
IFB-088
1A, 1B, 1E
Current stage: Phase 1
CKD Pharmaceuticals (Novartis)
CKD-510 (HDAC6 inhibitor)
1 and 2
Current stage: Phase 1
Augustine Therapeutics*
AGT100216
1 and 2
Current stage: Phase 1
Oryzon Genomics*
HDAC6 inhibitor
1A
Current stage: Preclinical
Actio Biosciences
TRPV4 modulator
2C
Current stage: Preclinical
Mitochondria in Motion
Mitofusion activators
2A
Current stage: Preclinical
Mitochondria Emotion
MiM111 & CPR1 (Mitofusion activators)
2A
Current stage: Preclinical
Samsara Therapeutics*
SAM1196 peripheral (autophagy enhancer)
1A
Current stage: Preclinical
AcuraStem (Takeda)**
PIKfyve inhibitor
4B1
Current stage: Preclinical
Lmito Therapeutics
LMT801
1A
Current stage: Preclinical
MitoR Therapeutics
MTRX
2A
Current stage: Preclinical
Avicenna
ROCK inhibitor (AV-016)
2A
Current stage: Preclinical
Alesta Therapeutics
ALE2 (kinase inhibitor)
2D
Current stage: Preclinical
Asha Therapeutics*
ASHA-623
2A
Current stage: Preclinical
Recursion Pharmaceuticals
Drug screen (undisclosed)
2A
Current stage: Discovery
AcuraStem*
Drug screen (undisclosed)
2A
Current stage: Discovery
ReviR Therapeutics
RTX-117
Broad
Current stage: Discovery
HDAX Therapeutics
HDAC6 inhibitor
2
Current stage: Discovery
Gene Therapy
Clinical Trials
Company
Name
CMT Type
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Alcyone Therapeutics
ACTX technology (Gene replacement; AAV9-IGHMBP2)
2S
Current stage: Phase 1
Sarepta Therapeutics
scAAV1.tMCK.NTF3
1A
Current stage: Preclinical
lonis
Gene knockdown; ASO
1A
Current stage: Preclinical
MAASiRNA
Gene knockdown; siRNA-squalene
1A
Current stage: Preclinical
Toolgen
TGT-001 (Gene editing; CRISPR/Cas9)
1A
Current stage: Preclinical
Nervosave Therapeutics
NVO-101 (Gene knockdown; siRNA)
1A
Current stage: Preclinical
Novartis (DTx Pharma)*
EKD060
1A
Current stage: Phase 1
Armatus Bio***
ARM-101 (Gene knockdown; miRNA)
1A
Current stage: Preclinical
Elpida Therapeutics***
ELP-02 (Gene replacement; AAV9)
4J
Current stage: Preclinical
Vanda Pharmaceuticals
VCA-894A
2S
Current stage: Preclinical
XIRNA Bio*
Gene replacement
2D
Current stage: Preclinical
Shift Pharmaceuticals*
Gene knockdown; PMO-ASO
1A
Current stage: Discovery
Nanite*
Polymer nanoparticle delivery (Gene knockdown; PMO-ASO)
1A
Current stage: Discovery
Other Biologics
Clinical Trials
Company
Name
CMT Type
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ENCell
EN001
1A
Current stage: Phase 1
Orthogonal Neuroscience
ORT247 (mAb inhibitor of EphA4 receptors)
1 and 2
Current stage: Phase 1
Cellatoz Pharmaceuticals
CLZ-2002/T-SC
1A
Current stage: Preclinical
Ageronix SA
AAT (plasma derived Alpha1-Antitrypsin)
1A
Current stage: Preclinical

*Funded by CMTRF
**CMTRF funded underlying technology
***CMTRF funded drug manufacturing

Updated 7/2025

Today, available treatments for CMT are designed to help people effectively manage disease symptoms. Drugs may be used to lessen pain, and orthopedic surgery to correct joint deformities. Physical and occupational therapy often incorporate strength training, muscle and ligament stretching and exercise to help with muscle weakness and pain. In addition, a range of medical devices including braces, walkers and wheelchairs are used to help maintain mobility, assisted ventilation can help with breathing issues and hearing aids help compensate for hearing loss.

However, with the identification over the past several decades of more than 100 different gene mutations underlying the various forms of CMT, scientists now have a broad range of targets at which to aim therapies that can modify the course of the disease.

CMTRF is working hard today to make good on our promise to deliver safe and effective treatments to people living with all forms of CMT. Our expectation is that the treatments of tomorrow will do more than manage symptoms. Tomorrow’s treatments, under development and testing now, will aim to modify the course of the disease whether by targeting a particular function, or changing a person’s genetic makeup.

Take Action